 |
||
|
|
In
the Spotlight Kinase-Dead BRAF and Oncogenic RAS Drive Tumor Progression through CRAF The RAS-ERK (extracellular signal-regulated protein kinase) MAPK (mitogen-activated protein kinase) signaling pathway regulates cell responses to environmental cues that include survival, proliferation, senescence, and differentiation. But, it also plays an important role ...Read More |
|
 |
 |
 |
|
Spectrum Pharmaceuticals Licenses Belinostat to TopoTarget Spectrum Pharmaceuticals has entered into a co-development and commercialization ... Abbott and Pierre Fabre to Develop and Commercialize Pre-Clinical mAb Abbott has signed an exclusive worldwide licensing agreement with Pierre Fabre SA ... Tenx Biopharma Licenses Zanolimumab from Genmab TTenX Biopharma has signed a licensing agreement to acquire exclusive worldwide rights... BioMarin to Acquire LEAD Therapeutics BioMarin Pharmaceutical has entered into a stock purchase agreement to acquire LEAD ... 3SBio and Ascentage Pharma to Develop and Commercialize Cancer Therapeutics 3SBio and Ascentage Pharma Group Corporation announced the formation of a strategic alliance ... |
Phosphorylation by Cdk2 is Required for Myc to Repress Ras-induced Senescence It has been known for over two decades that no more than two activated oncogenes... Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Kinase inhibitors have emerged as effective clinical therapies for cancers ... Chemical Proteomics Native Target Profiling of INNO-406 in CML Cells Expression of the oncogenic fusion protein BCR-ABL is the hallmark of chronic ... Mutant p53 Drives Invasion by Promoting Integrin Recycling p53 is a tumor suppressor protein whose function is frequently lost in cancers ... |
Denosumab Superior to Zometa in Prostate Cancer Patients with Bone Metastases Amgen announced that a pivotal, Phase III, head-to-head trial evaluating ... Phase II Trial of Picoplatin in mCRC meets Primary Endpoint Poniard Pharmaceuticals presented final data from a randomized, controlled ... Phase III Trial of Sutent in Patients with Pancreatic NETs meets Primary Endpoint Pfizer announced final results from a randomized Phase III trial of Sutent ... Survival Benefits with KRX-0401 in mCRC Treatment Keryx Biopharmaceuticals reported updated results from a Phase II trial ... |
 At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and bio tech companies. We currently work with leading pharmaceutical and biotech firms globally. CLICK HERE to visit SMARTANALYST |
 |
 |
|
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer Mutations within the KRAS proto-oncogene have predictive value... DNA Methylation Signatures Identify Biologically Distinct Subtypes in AML It has been appreciated in recent years that there are chemical codes ... AstraZeneca and Dako to Develop Companion Diagnostics for Cancer Treatments AstraZeneca and Dako Denmark have entered into a collaboration ... |
Herceptin Approved in EU for HER2-Positive Advanced Gastric Cancer Roche announced that the European Commission has approved Herceptin ... TYKERB Receives Accelerated Approval for 1st line Combination Treatment of HR+, HER2+/ErbB2+ Metastatic BC GlaxoSmithKline announced that the FDA has granted accelerated approval ... FDA Approves Rituxan plus Chemotherapy for CD20-positive CLL Genentech and Biogen Idec announced that the FDA has approved Rituxan ... Tasigna Receives FDA Priority Review for Newly Diagnosed Patients with Early-stage CLL Novartis announced that Tasigna (nilotinib), a Bcr-Abl-tyrosine-kinase-inhibitor ... |
|
|
The E-newsletter team: Dr. Anuradha Dhingra, Ms.Meenu Grover, Dr. Shirish Kumar, Ms. Sarika Manchanda, Dr. Vinamrata Bhatia. Copyright©2010 SMARTANALYST INDIA PVT LTD. All rights reserved CLICK HERE unsubscribe from the list |
||
